These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35365357)

  • 1. Polymorphisms in CTLA-4 predict de novo donor specific antibody formation after kidney transplantation.
    Ono K; Ide K; Kashihara M; Yamane H; Akimoto S; Tanimine N; Tahara H; Ohira M; Tanaka Y; Ohdan H
    Hum Immunol; 2022 Jun; 83(6):494-498. PubMed ID: 35365357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of blood transfusion post kidney transplantation on de novo human leukocytes antigen donor-specific antibody development and clinical outcomes in kidney transplant recipients: A systematic review and meta-analysis.
    Kang ZY; Ma S; Liu W; Liu C
    Transpl Immunol; 2023 Jun; 78():101801. PubMed ID: 36841513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Polymorphisms in Follicular Helper T Cell-Related Molecules Predispose Patients to De Novo Donor-Specific Antibody Formation After Kidney Transplantation.
    Ono K; Ide K; Nakano R; Sakai H; Tanimine N; Tahara H; Ohira M; Tanaka Y; Ohdan H
    Transplant Proc; 2023 May; 55(4):1048-1054. PubMed ID: 37031038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of CTLA-4 gene polymorphism with end-stage renal disease and renal allograft outcome.
    Misra MK; Kapoor R; Pandey SK; Sharma RK; Agrawal S
    J Interferon Cytokine Res; 2014 Mar; 34(3):148-61. PubMed ID: 24313821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CTLA-4 gene polymorphisms on long-term kidney allograft function in Han Chinese recipients.
    Guo Y; Gao J; Gao S; Shang M; Guo F
    Oncotarget; 2016 Apr; 7(17):23088-95. PubMed ID: 27081086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
    PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T-lymphocyte antigen 4 gene polymorphism influences the incidence of symptomatic human cytomegalovirus infection after renal transplantation.
    Misra MK; Pandey SK; Kapoor R; Sharma RK; Agrawal S
    Pharmacogenet Genomics; 2015 Jan; 25(1):19-29. PubMed ID: 25356901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Polymorphisms in T-Cell Activation Costimulatory/Inhibitory Signal Genes With Allograft Kidney Rejection Risk.
    Santiago JL; Sánchez-Pérez L; Pérez-Flores I; de la Higuera MAM; Romero NC; Querol-García J; Urcelay E; Sánchez-Fructuoso AI
    Front Immunol; 2021; 12():650979. PubMed ID: 34149691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
    Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
    Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eplet Mismatch Load and
    Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
    J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA4 polymorphisms and de novo malignancy risk after renal transplantation in Chinese recipients.
    Guo YF; Qiu JX; Guo F; Liu Y; Shang MH
    Biomed Res Int; 2015; 2015():986780. PubMed ID: 25667935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early immunosuppression treatment correlates with later de novo donor-specific antibody development after kidney and pancreas transplantation.
    Pelletier RP; Rajab AA; Diez A; DiPaola NR; Bumgardner GL; Elkhammas EA; Henry ML
    Clin Transplant; 2015 Dec; 29(12):1119-27. PubMed ID: 26382932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance of De Novo Donor Specific Antibody Based on the Type of Kidney Transplantation.
    Park WY; Kim Y; Paek JH; Jin K; Han S
    Transplant Proc; 2022 Mar; 54(2):335-340. PubMed ID: 35101323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo donor-specific antibody following BK nephropathy: The incidence and association with antibody-mediated rejection.
    Cheungpasitporn W; Kremers WK; Lorenz E; Amer H; Cosio FG; Stegall MD; Gandhi MJ; Schinstock CA
    Clin Transplant; 2018 Mar; 32(3):e13194. PubMed ID: 29315820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor-specific Antibody Surveillance and Graft Outcomes in Pediatric Kidney Transplant Recipients.
    Engen RM; Park GE; Schumacher CS; Gimferrer I; Warner P; Finn LS; Weiss NS; Smith JM
    Transplantation; 2018 Dec; 102(12):2072-2079. PubMed ID: 29863579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo donor-specific HLA antibodies in heart transplantation: Do transient de novo DSA confer the same risk as persistent de novo DSA?
    Moayedi Y; Fan CS; Tinckam KJ; Ross HJ; McCaughan JA
    Clin Transplant; 2018 Nov; 32(11):e13416. PubMed ID: 30276870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human leukocyte antigen epitope mismatch loads and the development of de novo donor-specific antibodies in cardiothoracic organ transplantation.
    Bedford A; Jervis S; Worthington J; Lowe M; Poulton K
    Int J Immunogenet; 2022 Feb; 49(1):30-38. PubMed ID: 34904369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Utility of Donor-specific Antibody Monitoring and the Role of Kidney Biopsy in Simultaneous Liver and Kidney Recipients With De Novo Donor-specific Antibodies.
    Parajuli S; Aziz F; Blazel J; Muth BL; Garg N; Mohamed M; Rice J; Mezrich JD; Hidalgo LG; Mandelbrot D
    Transplantation; 2021 Jul; 105(7):1548-1555. PubMed ID: 32732618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of a Steroid Avoidance Immunosuppression Regimen in Renal Transplant Patients With De Novo or Preformed Donor-Specific Antibodies: A Single-Center Study.
    Schutt R; Case J; Kurian SM; Spierling Bagsic SR; Barrick BL; Toll AE; Zhang Q; Reed EF; Quigley MM; Schaffer R; Fisher JS; Rice JC; Marsh CL
    Transplant Proc; 2021 Apr; 53(3):950-961. PubMed ID: 33293041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eplet mismatch scores and de novo donor-specific antibody development in simultaneous pancreas-kidney transplantation.
    Ladowski JM; Mullins H; Romine M; Kloda D; Young C; Hauptfeld-Dolejsek V; Houp J; Locke J
    Hum Immunol; 2021 Mar; 82(3):139-146. PubMed ID: 33390268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.